CAMBRIDGE, Mass., March 11,
2024 /PRNewswire/ -- Akebia Therapeutics®,
Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose
to better the lives of people impacted by kidney disease, today
announced plans to report fourth quarter and full year 2023
financial results on March 14, 2024.
Akebia will not host a conference call due to the proximity to the
anticipated March 27, 2024
Prescription Drug User Fee Act (PDUFA) target action date for
vadadustat, which is under review by the U.S. Food and Drug
Administration as a treatment for anemia due to chronic kidney
disease in adult patients on dialysis.
About Akebia Therapeutics
Akebia Therapeutics,
Inc. is a fully integrated biopharmaceutical company with the
purpose to better the lives of people impacted by kidney
disease. Akebia was founded in 2007 and is
headquartered in Cambridge,
Massachusetts. For more information, please visit our
website at www.akebia.com, which does not form a part
of this release.
Akebia Therapeutics Contact
Mercedes
Carrasco
mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-report-fourth-quarter-and-full-year-2023-financial-results-302085663.html
SOURCE Akebia Therapeutics, Inc.